DK1539977T3 - Fremstilling af tiacumicin - Google Patents
Fremstilling af tiacumicin Download PDFInfo
- Publication number
- DK1539977T3 DK1539977T3 DK03784766.2T DK03784766T DK1539977T3 DK 1539977 T3 DK1539977 T3 DK 1539977T3 DK 03784766 T DK03784766 T DK 03784766T DK 1539977 T3 DK1539977 T3 DK 1539977T3
- Authority
- DK
- Denmark
- Prior art keywords
- nutrient medium
- thiacumicin
- group
- microorganism
- tiacumicin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/44—Preparation of O-glycosides, e.g. glucosides
- C12P19/60—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin
- C12P19/62—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin the hetero ring having eight or more ring members and only oxygen as ring hetero atoms, e.g. erythromycin, spiramycin, nystatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Claims (12)
1. Fremgangsmåde til fremstilling af tiacumicin B, omfattende: dyrkning af en mikroorganisme i et næringsmedium til akkumulering af tiacumicin B i næringsmediet; og isolering af tiacumicin B fra næringsmediet; hvor næringsmediet omfatter mindst én adsorberharpiks, der er i stand til at adsorbere tiacumicin B.
2. Fremgangsmåde ifølge krav 1, hvorved næringsmediet omfatter 0,5 vægt-% -15 vægt-% af den mindst ene adsorberharpiks, som er i stand til at adsorbere tiacumicin B.
3. Fremgangsmåde ifølge krav 1, der omfatter dyrkning af en mikroorganisme, der er i stand til at producere tiacumicin B i et næringsmedium omfattende mindst ét adsorberingsmiddel, som er i stand til at adsorbere tiacumicin B under dyrkningen, hvor adsorberingsmidlet udvælges fra gruppen bestående af en omvendt-fase-silicagel, Amberlite® XAD16, XAD16HP, XAD2, XAD7HP, XAD1180, XAD1600, IRC50 og Duolite XAD761, og akkumulering af tiacumicin B i næringsmediet.
4. Fremgangsmåde ifølge krav 1, hvorved mikroorganismen er Dactylosporangium aurantiacum NRRL 18085.
5. Fremgangsmåde ifølge krav 1, hvorved tiacumicin B isoleres fra næringsmediet under anvendelse af teknikker udvalgt fra gruppen bestående af: sigtning og fjernelse af uønsket materiale ved eluering med mindst ét opløsningsmiddel eller en opløsningsmiddelblanding; ekstraktion med mindst ét opløsningsmiddel eller en opløsningsmiddelblanding; krystallisation; kromatografisk separation; high-performance væskechromatografi (FIPLC); MPLC; triturering; og ekstraktion med mættet saltopløsning med mindst ét opløsningsmiddel eller en opløsningsmiddelblanding.
6. Fremgangsmåde ifølge krav 1, hvorved mikroorganismen dyrkes ved en temperatur fra ca. 25 °C til 35 °C og ved en pH fra ca. 6,0 til 8,0.
7. Fremgangsmåde ifølge krav 1, hvorved næringsmediet efter behov tilføres én eller flere carbonkilder, udvalgt fra gruppen bestående af glucose, saccharose, stivelse, melasse, dextriner, valle, glycerol, lipiderog majsmel.
8. Fremgangsmåde ifølge krav 1, hvorved næringsmediet efter behov tilføres en yderligere carbonkilde.
9. Fremgangsmåde ifølge krav 1, hvorved næringsmediet omfatter én eller flere nitrogenkilder/organiske kilder, der kan understøtte vækst af mikroorganismer, udvalgt fra gruppen bestående af kødekstrakt, sojabønnemel, helgær, gærekstrakt, sojamel, pepton, casaminosyre, fiskepulver, majsstøbevæske, ammoniumsalte, casein og aminosyrer.
10. Fremgangsmåde ifølge krav 9, hvorved næringsmediet omfatter fiskepulver.
11. Fremgangsmåde ifølge krav 1, hvorved næringsmediet omfatter ét eller flere uorganiske salte, der kan understøtte vækst af mikroorganismer, udvalgt fra gruppen bestående af K2FIPO4, MgSO^FhO og CaCC>3.
12. Fremgangsmåde ifølge krav 3, hvorved omvendt-fase-silicagelen udvælges fra gruppen bestående af KP-C18, KP-C 18-WP og KP-C18FIS.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39995602P | 2002-07-29 | 2002-07-29 | |
PCT/US2003/021977 WO2004014295A2 (en) | 2002-07-29 | 2003-07-15 | Tiacumicin production |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1539977T3 true DK1539977T3 (da) | 2014-11-17 |
Family
ID=31715689
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK03784766.2T DK1539977T3 (da) | 2002-07-29 | 2003-07-15 | Fremstilling af tiacumicin |
Country Status (18)
Country | Link |
---|---|
US (4) | US7507564B2 (da) |
EP (2) | EP1539977B1 (da) |
JP (3) | JP2005534332A (da) |
KR (1) | KR100972542B1 (da) |
CN (1) | CN100519757C (da) |
AU (1) | AU2003251902B2 (da) |
BE (1) | BE2015C017I2 (da) |
CA (1) | CA2494742C (da) |
CY (1) | CY2015015I1 (da) |
DK (1) | DK1539977T3 (da) |
ES (1) | ES2527052T3 (da) |
FR (1) | FR15C0028I2 (da) |
HU (1) | HUS1500016I1 (da) |
LU (1) | LU92684I2 (da) |
NL (1) | NL300727I2 (da) |
PT (1) | PT1539977E (da) |
SI (1) | SI1539977T1 (da) |
WO (1) | WO2004014295A2 (da) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1539977E (pt) * | 2002-07-29 | 2015-01-14 | Optimer Pharmaceuticals Inc | Produção de tiacumicina |
US20070105791A1 (en) * | 2002-07-29 | 2007-05-10 | Optimer Pharmaceuticals, Inc. | Method of treating clostridium difficile-associated diarrhea |
HUE043945T2 (hu) * | 2004-05-14 | 2019-09-30 | Merck Sharp & Dohme | Betegségek kezelése antibiotikumok használatával összefüggésben |
US7906489B2 (en) * | 2004-05-14 | 2011-03-15 | Optimer Pharmaceuticals, Inc. | 18-membered macrocycles and analogs thereof |
AU2012200784B2 (en) * | 2005-01-31 | 2013-07-11 | Merck Sharp & Dohme Llc | 18-membered macrocycles and analogs thereof |
US7378508B2 (en) * | 2007-01-22 | 2008-05-27 | Optimer Pharmaceuticals, Inc. | Polymorphic crystalline forms of tiacumicin B |
AU2005327308B2 (en) * | 2005-01-31 | 2011-11-10 | Merck Sharp & Dohme Llc | 18-membered macrocycles and analogs thereof |
CN101340919B (zh) * | 2005-10-21 | 2011-12-07 | 奥普蒂姆药物公司 | 治疗艰难梭菌相关的腹泻的方法 |
US20080176927A1 (en) * | 2007-01-19 | 2008-07-24 | Optimer Pharmaceuticals, Inc. | Compositions of stable tiacumicins |
KR100891313B1 (ko) * | 2007-08-17 | 2009-03-31 | (주) 제노텍 | 담체로 작용하는 흡착성 수지의 제공에 의한 트리사이클로화합물의 생산 및 추출 방법 |
TWI326284B (en) * | 2007-10-26 | 2010-06-21 | Echem Hightech Co Ltd | Derivatives of tiacumicin b as anti-cancer agents |
TWI523654B (zh) | 2007-11-27 | 2016-03-01 | 默沙東藥廠 | 抗生素巨環化合物以及其製造及使用之方法 |
WO2011100670A1 (en) * | 2010-02-15 | 2011-08-18 | Abbott Laboratories | Process for the preparation of scyllo-inositol |
AU2011316540A1 (en) | 2010-10-13 | 2014-04-10 | Elan Pharmaceuticals, Inc. | Methods of synthesis of scyllitol and related compounds |
CN102115757B (zh) * | 2010-12-14 | 2015-10-28 | 中国科学院南海海洋研究所 | 台勾霉素的生物合成基因簇及其应用 |
ITMI20120559A1 (it) * | 2012-04-05 | 2013-10-06 | Olon Spa | Procedimento migliorato per la produzione di tiacumicina b |
ITMI20120560A1 (it) * | 2012-04-05 | 2013-10-06 | Olon Spa | Procedimento per la purificazione della tiacumicina b |
CN104768963A (zh) * | 2012-05-10 | 2015-07-08 | 特瓦制药厂有限公司 | 非达霉素的固态形式及其制备方法 |
US9970041B2 (en) * | 2012-08-07 | 2018-05-15 | Olon S.P.A. | Procedure for the production of tiacumicin B |
ITMI20121406A1 (it) * | 2012-08-07 | 2014-02-08 | Olon Spa | Procedimento per la produzione di tiacumicina b |
ITMI20130856A1 (it) * | 2013-05-27 | 2014-11-28 | Olon Spa | Procedimento per la produzione di tiacumicina b |
CN102993251B (zh) * | 2012-12-17 | 2016-03-16 | 苏州纳微科技有限公司 | 一种用高效液相色谱纯化台勾霉素b的方法 |
JO3464B1 (ar) | 2013-01-15 | 2020-07-05 | Astellas Pharma Europe Ltd | التركيبات الخاصة بمركبات التياكوميسين |
IN2013MU01498A (da) * | 2013-04-23 | 2015-04-24 | Concord Biotech Ltd | |
CN103275152B (zh) * | 2013-05-29 | 2015-11-18 | 华北制药集团新药研究开发有限责任公司 | 一种高纯度非达霉素的制备方法 |
CN103275153B (zh) * | 2013-06-27 | 2016-03-23 | 华北制药集团新药研究开发有限责任公司 | 一种非达霉素晶体的制备方法 |
CN104418925B (zh) * | 2013-09-05 | 2018-09-28 | 重庆乾泰生物医药有限公司 | 一种制备高纯度非达霉素的方法 |
CN104513286B (zh) * | 2013-09-27 | 2018-08-17 | 博瑞生物医药(苏州)股份有限公司 | 一种分离纯化非达米星的方法 |
CN104560766B (zh) * | 2013-10-16 | 2017-07-28 | 浙江海正药业股份有限公司 | 一种游动放线菌菌株及其应用 |
CN104561198B (zh) * | 2013-10-18 | 2019-04-12 | 重庆乾泰生物医药有限公司 | 一种发酵生产非达霉素的方法 |
BR112016013582B1 (pt) * | 2013-12-20 | 2022-04-19 | Xellia Pharmaceuticals Aps | Processo para preparação de tiacumicina |
CN104846044B (zh) * | 2014-02-17 | 2019-02-01 | 上海医药工业研究院 | 一种提高非达霉素产量的发酵培养基 |
WO2015127955A1 (en) | 2014-02-25 | 2015-09-03 | Olon S.P.A. | A new polymorph of tiacumicin b and process for preparation thereof |
JP2017507994A (ja) | 2014-03-18 | 2017-03-23 | クセリア ファーマシューティカルズ エーピーエスXellia Pharmaceuticals ApS | チアクマイシンbの新たな多形及び新たな固体状態 |
CN103880904B (zh) * | 2014-03-28 | 2016-08-24 | 华北制药集团新药研究开发有限责任公司 | 非达霉素晶型i及其制备方法 |
CN104946708B (zh) * | 2014-03-28 | 2018-06-12 | 上海医药工业研究院 | 一种生产非达霉素的发酵培养基以及发酵方法 |
CA2948400A1 (en) | 2014-05-09 | 2015-11-12 | Astellas Pharma Europe Ltd | Treatment regimen tiacumicin compound |
CN104098637B (zh) * | 2014-07-09 | 2017-01-04 | 浙江海正药业股份有限公司 | 一种纯化非达霉素的方法 |
CA2990961A1 (en) | 2015-07-03 | 2017-01-12 | Astellas Pharma Europe Ltd. | Novel dosage regimen tiacumicin compound |
IL251499B (en) * | 2017-04-02 | 2019-02-28 | Efraty Avi | Reverse osmosis installation in a closed circuit with a hydraulic arm for desalination with low energy consumption and a high recovery ratio |
CN107236686B (zh) * | 2017-06-21 | 2019-10-15 | 杭州华东医药集团新药研究院有限公司 | 一种桔橙指孢囊菌及其在调控微生物代谢物非达霉素中的应用 |
CN114084964B (zh) * | 2020-08-24 | 2023-02-24 | 中国石油化工股份有限公司 | 一种芳香有机化合物废水生物处理促进剂及制备方法和应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3000792A (en) | 1957-05-21 | 1961-09-19 | Merck & Co Inc | Antibiotic adsorption process |
GB1458512A (en) * | 1973-11-22 | 1976-12-15 | Lepetit Spa | Antibiotic substance |
US4632902A (en) * | 1981-08-20 | 1986-12-30 | Becton, Dickinson And Company | Method for detecting biological activity in a body fluid |
US4843008A (en) * | 1984-12-24 | 1989-06-27 | Yamanouchi Pharmaceutical Co., Ltd. | Novel microorganisms and a novel process for producing antibiotics |
US4918174A (en) | 1986-09-26 | 1990-04-17 | Abbott Laboratories | Tiacumicin compounds |
US5242815A (en) * | 1990-01-24 | 1993-09-07 | Shin-Etsu Chemical Co., Ltd. | Process for preparation of streptovaricin |
CA2384535C (en) * | 1991-03-04 | 2006-08-15 | Bayer Corporation | Automated analyzer |
US5767096A (en) * | 1996-07-12 | 1998-06-16 | Abbott Laboratories | Bromotiacumicin compounds |
CN100344627C (zh) * | 1996-11-18 | 2007-10-24 | 生物技术研究有限公司(Gbf) | 埃坡霉素c、其制备方法以及作为细胞抑制剂和植物保护剂的应用 |
JP2000072760A (ja) * | 1998-06-19 | 2000-03-07 | Ajinomoto Co Inc | 新規シストチアゾール類縁体 |
JP2000053514A (ja) * | 1998-08-06 | 2000-02-22 | Aquas Corp | レジオネラ属細菌が生産する殺菌性物質、これを用いた殺菌剤、水処理剤、スライム抑制剤、及びこれらの製造方法 |
JP2000239266A (ja) * | 1999-02-17 | 2000-09-05 | Ajinomoto Co Inc | 新規ポリエン系抗生物質 |
ATE444368T1 (de) * | 2000-04-28 | 2009-10-15 | Kosan Biosciences Inc | Kristallines epothilon d |
PT1539977E (pt) * | 2002-07-29 | 2015-01-14 | Optimer Pharmaceuticals Inc | Produção de tiacumicina |
-
2003
- 2003-07-15 PT PT37847662T patent/PT1539977E/pt unknown
- 2003-07-15 DK DK03784766.2T patent/DK1539977T3/da active
- 2003-07-15 CN CNB038180162A patent/CN100519757C/zh not_active Expired - Lifetime
- 2003-07-15 EP EP03784766.2A patent/EP1539977B1/en not_active Expired - Lifetime
- 2003-07-15 AU AU2003251902A patent/AU2003251902B2/en not_active Expired
- 2003-07-15 ES ES03784766.2T patent/ES2527052T3/es not_active Expired - Lifetime
- 2003-07-15 WO PCT/US2003/021977 patent/WO2004014295A2/en active Application Filing
- 2003-07-15 CA CA2494742A patent/CA2494742C/en not_active Expired - Lifetime
- 2003-07-15 JP JP2004527605A patent/JP2005534332A/ja active Pending
- 2003-07-15 EP EP20140187987 patent/EP2860241A1/en not_active Withdrawn
- 2003-07-15 KR KR1020057001613A patent/KR100972542B1/ko active IP Right Grant
- 2003-07-15 SI SI200332404T patent/SI1539977T1/sl unknown
- 2003-07-15 US US10/520,863 patent/US7507564B2/en not_active Expired - Lifetime
-
2009
- 2009-02-04 US US12/365,230 patent/US20100028970A1/en not_active Abandoned
-
2010
- 2010-05-10 JP JP2010108270A patent/JP5729919B2/ja not_active Expired - Lifetime
-
2012
- 2012-06-12 US US13/494,887 patent/US8728796B2/en not_active Expired - Lifetime
-
2013
- 2013-06-14 JP JP2013125445A patent/JP5907931B2/ja not_active Expired - Lifetime
-
2014
- 2014-05-19 US US14/281,496 patent/US20140296498A1/en not_active Abandoned
-
2015
- 2015-03-25 NL NL300727C patent/NL300727I2/nl unknown
- 2015-03-26 LU LU92684C patent/LU92684I2/xx unknown
- 2015-03-26 BE BE2015C017C patent/BE2015C017I2/fr unknown
- 2015-03-27 FR FR15C0028C patent/FR15C0028I2/fr active Active
- 2015-03-27 HU HUS1500016C patent/HUS1500016I1/hu unknown
- 2015-04-03 CY CY2015015C patent/CY2015015I1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1539977T3 (da) | Fremstilling af tiacumicin | |
JP2917305B2 (ja) | Fr−901155物質およびその生産法 | |
CZ390592A3 (en) | Process for preparing 4,5-dihydrogendanamycin and hydroquinone thereof and the use of such compounds | |
WO2005038009A2 (en) | Production of tacrolimus (fk-506) using new streptomyces species | |
EP0001709B1 (en) | Deoxynarasin antibiotics, their production and use | |
JPH0763387B2 (ja) | テイコプラニン‐様誘導体 | |
JPH04230399A (ja) | 微生物の新規な免疫抑制発酵産物 | |
JP3830964B2 (ja) | 海洋放線菌から単離した新規なチオデプシペプチド | |
NO305132B1 (no) | FremgangsmÕte for fremstilling av Balhimycin og biologisk ren kultur | |
KR930001870B1 (ko) | 신규의 항진균 물질 krf-001 복합체의 발효 및 정제방법 | |
EP0818464B1 (en) | Methylsulfomycin l, a process for its production and its use | |
CA2444907C (en) | Substantially pure glycopeptide antibiotics ac-98-1; ac-98-2; ac-98-3; ac-98-4 and ac-98-5 | |
EP0531642B1 (en) | Antibiotic LL-E19020 Zeta and LL-E 19029 Eta | |
US3549502A (en) | Process for the production of neutramycin | |
KR820002138B1 (ko) | A-40104 항생물질의 제조방법 | |
JP2002212187A (ja) | イソキノサイクリン系抗生物質 | |
JP2000086627A (ja) | 抗菌性物質be−54476及びその製造法 | |
JPH03209384A (ja) | 新規な微生物変換生成物 | |
JPH0311096A (ja) | 新規マクロライド抗生物質マイシナミシン類およびその製造法 | |
JPH05255365A (ja) | 抗生物質LL−E19020エプシロン(ε)及びLL−E19020エプシロン1 | |
JPWO2007132937A1 (ja) | 新規な抗生物質、ビスポライドA1、A2およびA3ならびにビスポライドB1、B2a、B2bおよびB3と、それら抗生物質の製造方法 |